Podcast Episodes
Back to Search
Actinogen Medical's XanaMIA Alzheimer’s trial nears November results
Episode 14911
Actinogen Medical CFO Will Souter talked with Proactive about the completion of the final patient visit in the company’s pivotal XanaMIA Phase 2b/3 A…
3 weeks, 2 days ago
ReconAfrica reports Thermogenic Gas at KW1X as horizontal drilling nears
Episode 14907
ReconAfrica CEO Brian Reinsborough joined Steve Darling from Proactive to provide an update on the company’s expanding African energy portfolio, high…
3 weeks, 2 days ago
HANetf’s Harry Halewood explains option income strategies and covered call trade-offs
Episode 14906
HANetf Product Specialist Harry Halewood joined Steve Darling from Proactive to explain how option income strategies, including covered calls, can be…
3 weeks, 2 days ago
BrenX expands Hungary site, advancing first integrated industrial energy center
Episode 14905
BrenX CEO Nir Brenmiller joined Steve Darling from Proactive to announce that the company has entered into a definitive real estate sale and purchase…
3 weeks, 2 days ago
Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial
Episode 14904
Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce an important milestone in the company’s neuroimmunology pipelin…
3 weeks, 2 days ago
MetaOptics expands U.S. investor reach with OTCQX debut under ticker MOTLY
Episode 14899
MetaOptics Technologies CFO Alex Chu joined Steve Darling from Proactive to discuss the company’s latest milestone as it expands its presence in the …
3 weeks, 2 days ago
Cordiant Digital Infrastructure sees AI demand drive growth as revenue climbs 20%
Episode 14898
Cordiant Digital Infrastructure Executive Chairman Steve Marshall and Chief Finanncial Officer Andrew Ewe joined Steve Darling from Proactive to dis…
3 weeks, 2 days ago
Bango delivers strong H1 growth as subscription revenue, EBITDA and ARR surge
Episode 14897
Bango Plc. CEO Paul Larbey joined Steve Darling from Proactive to discuss the company’s strong first-half results, highlighting continued momentum in…
3 weeks, 2 days ago
Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections
Episode 14896
Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper joined Steve Darling from Proactive to announce a significant clinical milestone for the company, c…
3 weeks, 2 days ago
Poolbeg Pharma CEO: 'Incredible progress' with POLB 001 as cash runway extends to 2028
Episode 14886
Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion about the company's interim results for the first half of…
3 weeks, 2 days ago